标题
Pasireotide in the treatment of neuroendocrine tumors: a review of the literature
作者
关键词
-
出版物
ENDOCRINE-RELATED CANCER
Volume 25, Issue 6, Pages R351-R364
出版商
Bioscientifica
发表日期
2018-04-12
DOI
10.1530/erc-18-0010
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- High interlaboratory and interobserver agreement of somatostatin receptor immunohistochemical determination and correlation with response to somatostatin analogs
- (2018) Atsuko Kasajima et al. HUMAN PATHOLOGY
- Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects
- (2017) Gherardo Mazziotti et al. EXPERT OPINION ON PHARMACOTHERAPY
- Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial
- (2017) Piero Ferolla et al. LANCET ONCOLOGY
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents
- (2017) Marianne Pavel et al. NEUROENDOCRINOLOGY
- Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors
- (2017) James Yao et al. OncoTargets and Therapy
- Role of tumor microenvironment in tumorigenesis
- (2017) Maonan Wang et al. Journal of Cancer
- Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1–Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression
- (2016) Gerard V. Walls et al. ENDOCRINOLOGY
- Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells
- (2016) Roxanne C.S. van Adrichem et al. NEUROENDOCRINOLOGY
- Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts
- (2016) Siham Moatassim-Billah et al. Oncotarget
- Somatostatin Receptor 2 and 5 Expressions in Gastroenteropancreatic Neuroendocrine Tumors in Turkey
- (2015) Omer Yerci et al. Asian Pacific Journal of Cancer Prevention
- Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer
- (2015) Yaman Suleiman et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance
- (2015) C. Duluc et al. EMBO Molecular Medicine
- Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies
- (2015) Amit Mahipal et al. INVESTIGATIONAL NEW DRUGS
- Expression of Somatostatin Receptors 1-5 and Dopamine Receptor 2 in Lung Carcinoids: Implications for a Therapeutic Role
- (2015) George Kanakis et al. NEUROENDOCRINOLOGY
- Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues
- (2015) Edward Wolin et al. Drug Design Development and Therapy
- RAF signaling in neuroendocrine neoplasms: From bench to bedside
- (2014) Nicola Fazio et al. CANCER TREATMENT REVIEWS
- Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures
- (2014) A. Mohamed et al. ENDOCRINE-RELATED CANCER
- Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment
- (2014) Annemiek Walenkamp et al. ENDOCRINE-RELATED CANCER
- Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors
- (2014) M Cives et al. ENDOCRINE-RELATED CANCER
- Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
- (2014) Martyn E. Caplin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study
- (2013) Edward M. Wolin et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies
- (2013) Federica Barbieri et al. DRUG DISCOVERY TODAY
- Hyperglycemia Associated With Pasireotide: Results From a Mechanistic Study in Healthy Volunteers
- (2013) Robert R. Henry et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The Novel Somatostatin Receptor 2/Dopamine Type 2 Receptor Chimeric Compound BIM-23A758 Decreases the Viability of Human GOT1 Midgut Carcinoid Cells
- (2013) Kathrin Zitzmann et al. NEUROENDOCRINOLOGY
- Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors
- (2012) Jennifer A Chan et al. ENDOCRINE-RELATED CANCER
- Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study
- (2012) Larry K Kvols et al. ENDOCRINE-RELATED CANCER
- Signaling Pathways as Specific Pharmacologic Targets for Neuroendocrine Tumor Therapy: RET, PI3K, MEK, Growth Factors, and Notch
- (2012) Yvette Carter et al. NEUROENDOCRINOLOGY
- Synergistic Effect of Pasireotide and Teriflunomide in Carcinoids in vitro
- (2012) Yash Somnay et al. NEUROENDOCRINOLOGY
- Differential expression of somatostatin receptors 1–5 in neuroendocrine carcinoma of the lung
- (2012) Koji Tsuta et al. PATHOLOGY RESEARCH AND PRACTICE
- Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model
- (2012) Thomas J. Quinn et al. SURGERY
- Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT
- (2011) Bernhard Svejda et al. CANCER
- SOM230 combined with celecoxib prolongs the survival in nude mice with HepG-2 xenografts
- (2011) Yan Xie et al. CANCER BIOLOGY & THERAPY
- Expression of somatostatin receptors, dopamine D2 receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas
- (2011) A. Saveanu et al. ENDOCRINE-RELATED CANCER
- The role of somatostatin and dopamine D2 receptors in endocrine tumors
- (2011) Federico Gatto et al. ENDOCRINE-RELATED CANCER
- Somatostatin-Dopamine Chimeras: A Novel Approach to Treatment of Neuroendocrine Tumors
- (2011) M. Culler HORMONE AND METABOLIC RESEARCH
- Current Scientific Rationale for the Use of Somatostatin Analogs and mTOR Inhibitors in Neuroendocrine Tumor Therapy
- (2011) Corinne Bousquet et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: A potential mechanism of therapeutic limitation of mTOR inhibitor
- (2011) Shinya Iida et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Clinical Significance of Protein Expression of Cyclooxygenase-2 and Somatostatin Receptors in Gastroenteropancreatic Neuroendocrine Tumors
- (2011) Hee Sung Kim et al. Cancer Research and Treatment
- Compensatory activation of Akt in response to mTOR and Raf inhibitors – A rationale for dual-targeted therapy approaches in neuroendocrine tumor disease
- (2010) Kathrin Zitzmann et al. CANCER LETTERS
- Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids
- (2010) Maria Chiara Zatelli et al. ENDOCRINE-RELATED CANCER
- Identification of a Novel Raf-1 Pathway Activator that Inhibits Gastrointestinal Carcinoid Cell Growth
- (2010) M. R. Cook et al. MOLECULAR CANCER THERAPEUTICS
- Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases
- (2009) L. Righi et al. ANNALS OF ONCOLOGY
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
- (2009) Anja Rinke et al. JOURNAL OF CLINICAL ONCOLOGY
- Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
- (2009) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- ZM447439, a Novel Promising Aurora Kinase Inhibitor, Provokes Antiproliferative and Proapoptotic Effects Alone and in Combination with Bio- and Chemotherapeutic Agents in Gastroenteropancreatic Neuroendocrine Tumor Cell Lines
- (2009) I. Georgieva et al. NEUROENDOCRINOLOGY
- Somatostatin inhibits colon cancer cell growth through cyclooxygenase-2 downregulation
- (2008) R Colucci et al. BRITISH JOURNAL OF PHARMACOLOGY
- Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines
- (2008) Mark Kidd et al. CANCER
- Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours
- (2008) Nicole Unger et al. CLINICAL ENDOCRINOLOGY
- Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors
- (2008) A. Moreno et al. ENDOCRINE-RELATED CANCER
- Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells
- (2008) Daniela Pasquali et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started